If you or a loved one is taking Reglan (metoclopramide) and notices unusual, repetitive movements of the face, tongue, or limbs, these could be early signs of tardive dyskinesia—a potentially irreversible neurological condition. Building on decades of clinical research into medication-induced movement disorders, this page provides a clear overview of what to watch for and how monitoring is approached in West Virginia.
Building on the general awareness of medication risks, the specific link between Reglan and Tardive Dyskinesia (TD) requires a focused examination. Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat nausea, vomiting, and gastroparesis. Its mechanism of action can lead to extrapyramidal side effects, including tardive dyskinesia (TD) (https://pubmed.ncbi.nlm.nih.gov/34712535/). TD is a hyperkinetic movement disorder caused by the use of dopamine receptor-blocking agents (DRBAs), a category that includes metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34703232/). The condition is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is associated with increased comorbidities, social stigmatization, and impaired physical and mental health (https://pubmed.ncbi.nlm.nih.gov/34703232/). The risk of developing TD from Reglan increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The prescribing information includes a boxed warning stating that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration of treatment, with periodic reassessment of the need for continued therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks; if longer use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The timeline between exposure and documented harm can vary. While TD is often associated with prolonged use, cases have been reported after a single dose. One case report describes a postoperative gynecological patient who developed dyskinetic movements after intraoperative administration of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). This suggests that even short-term exposure can trigger TD, particularly in individuals with underlying risk factors. Older age is associated with increased risk of TD and with the emergence of TD occurring after shorter treatment durations and lower dosages of DRBAs (https://pubmed.ncbi.nlm.nih.gov/34703232/). Once present, TD tends to persist despite dose adjustment or discontinuation of the causative agent (https://pubmed.ncbi.nlm.nih.gov/34703232/).
The adequacy of warnings regarding Reglan and TD is addressed in the prescribing information. The boxed warning explicitly states that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warnings and precautions section further notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis because it may mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label advises avoiding concomitant use of other drugs known to cause TD, and avoiding use in patients with Parkinson's Disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If symptoms occur, the label instructs to discontinue Reglan and seek immediate medical attention (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For affected patients, causation considerations involve establishing a temporal relationship between Reglan exposure and the onset of TD symptoms, as well as ruling out other potential causes. The known pharmacological mechanism—dopamine D2-receptor blockade—provides a plausible biological pathway linking Reglan to TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). However, individual risk factors such as older age, duration of treatment, and cumulative dosage can influence the likelihood of developing TD (https://pubmed.ncbi.nlm.nih.gov/34703232/). Patients who develop TD after Reglan use may face challenges in treatment, as the condition can be irreversible and may persist despite discontinuation of the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The boxed warning emphasizes that Reglan is contraindicated in patients with a history of TD, underscoring the importance of avoiding re-exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In summary, the evidence establishes a clear causal link between Reglan and TD, supported by pharmacological mechanisms, clinical case reports, and regulatory warnings. The risk is dose- and duration-dependent, but can occur after short-term use, especially in vulnerable populations. Adequate warnings are provided in the prescribing information, but the potential for irreversible harm underscores the need for careful patient selection, short treatment durations, and vigilant monitoring.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent that can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The risk increases with longer treatment duration and higher cumulative doses, but cases have been reported even after short-term use. The prescribing information includes a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The timeline varies. While TD is often associated with prolonged use (weeks to months), cases have been reported after a single dose, especially in vulnerable individuals. Older age and higher dosages may shorten the time to onset. Once developed, TD often persists even after stopping the drug (https://pubmed.ncbi.nlm.nih.gov/34703232/).
If you experience involuntary movements, especially of the face or tongue, discontinue Reglan and seek immediate medical attention. The prescribing information advises stopping the drug and consulting a healthcare provider. Do not restart Reglan without medical advice (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.